Top

Published in:

01-03-2012 | Original Paper

Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease

Authors: Christoffer Rosén, Ulf Andreasson, Niklas Mattsson, Jan Marcusson, Lennart Minthon, Niels Andreasen, Kaj Blennow, Henrik Zetterberg

Published in: NeuroMolecular Medicine | Issue 1/2012

Abstract

The amyloid cascade hypothesis on the pathogenesis of Alzheimer’s disease (AD) states that amyloid β (Aβ) accumulation in the brain is a key factor that initiates the neurodegenerative process. Aβ is generated from amyloid precursor protein (APP) through sequential cleavages by BACE1 (the major β-secretase in the brain) and γ-secretase. The purpose of this study was to characterize APP metabolism in vivo in AD patients versus cognitively healthy subjects by examining alterations in cerebrospinal fluid (CSF) biomarkers. We measured BACE1 activity and concentrations of α- and β-cleaved soluble APP (sAPPα and sAPPβ, respectively) and Aβ40 in CSF, biomarkers that all reflect the metabolism of APP, in 75 AD patients and 65 cognitively healthy controls. These analytes were also applied in a multivariate model to determine whether they provided any added diagnostic value to the core CSF AD biomarkers Aβ42, T-tau, and P-tau. We found no significant differences in BACE1 activity or sAPPα, sAPPβ, and Aβ40 concentrations between AD patients and controls. A multivariate model created with all analytes did not improve the separation of AD patients from controls compared with using the core AD biomarkers alone, highlighting the strong diagnostic performance of Aβ42, T-tau, and P-tau for AD. However, AD patients in advanced clinical stage, as determined by low MMSE score (≤20), had lower BACE1 activity and sAPPα, sAPPβ, and Aβ40 concentrations than patients with higher MMSE score, suggesting that these markers may be related to the severity of the disease.

American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders: DSM-III-R (3rd ed.). Washington, DC: American Psychiatric Association.

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., et al. (1999). Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Archives of Neurology, 56, 673–680.PubMedCrossRef

Blennow, K., de Leon, M. J., & Zetterberg, H. (2006). Alzheimer’s disease. Lancet, 368, 387–403. doi:10.1016/S0140-6736(06)69113-7.PubMedCrossRef

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 6, 131–144.PubMedCrossRef

Blennow, K., Wallin, A., Agren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995). Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Molecular and Chemical Neuropathology, 26, 231–245.PubMedCrossRef

Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., et al. (2007). Longitudinal stability of CSF biomarkers in Alzheimer’s disease. Neuroscience Letters, 419, 18–22.PubMedCrossRef

Bylesjö, M., Rantalainen, M., Cloarec, O., Nicholson, J. K., Holmes, E. A., & Trygg, J. (2006). OPLS discriminant analysis: Combining the strengths of PLS-DA and SIMCA classification. Journal of Chemometrics, 20, 341–351.CrossRef

Cirrito, J. R., Kang, J. E., Lee, J., Stewart, F. R., Verges, D. K., Silverio, L. M., et al. (2008). Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron, 58, 42–51.PubMedCrossRef

Fagan, A. M., Shaw, L. M., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., et al. (2011). Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1–42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Archives of Neurology, 68, 1137–1144.PubMedCrossRef

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.PubMedCrossRef

Fukumoto, H., Cheung, B. S., Hyman, B. T., & Irizarry, M. C. (2002). Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Archives of Neurology, 59, 1381–1389.PubMedCrossRef

Gisslén, M., Krut, J., Andreasson, U., Blennow, K., Cinque, P., Brew, B. J., et al. (2009). Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurology, 9, 63. doi:10.1186/1471-2377-9-63.PubMedCrossRef

Höistad, M., Samskog, J., Jacobsen, K. X., Olsson, A., Hansson, H. A., Brodin, E., et al. (2005). Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. Brain Research, 1041, 167–180.PubMedCrossRef

Holsinger, R. M., Lee, J. S., Boyd, A., Masters, C. L., & Collins, S. J. (2006). CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology, 67, 710–712.PubMedCrossRef

Holsinger, R. M., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002). Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Annals of Neurology, 51, 783–786.PubMedCrossRef

Holsinger, R. M., McLean, C. A., Collins, S. J., Masters, C. L., & Evin, G. (2004). Increased beta-secretase activity in cerebrospinal fluid of Alzheimer’s disease subjects. Annals of Neurology, 55, 898–899.PubMedCrossRef

Jack, C. R., Jr, Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurology, 9, 119–128.PubMedCrossRef

Johansson, P., Mattsson, N., Hansson, O., Wallin, A., Johansson, J. O., Andreasson, U., et al. (2011). Cerebrospinal fluid biomarkers for Alzheimer’s disease: Diagnostic performance in a homogeneous mono-center population. Journal of Alzheimers Disease, 24, 537–546.

Johnston, J. A., Liu, W. W., Todd, S. A., Coulson, D. T., Murphy, S., Irvine, G. B., et al. (2005). Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer’s disease. Biochemical Society Transactions, 33, 1096–1100.PubMedCrossRef

Lewczuk, P., Kamrowski-Kruck, H., Peters, O., Heuser, I., Jessen, F., Popp, J., et al. (2010). Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: A multicenter study. Molecular Psychiatry, 15, 138–145.PubMedCrossRef

Mattson, M. P., Barger, S. W., Furukawa, K., Bruce, A. J., Wyss-Coray, T., Mark, R. J., et al. (1997). Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer’s disease. Brain Research Reviews, 23, 47–61.PubMedCrossRef

Mattsson, N., Axelsson, M., Haghighi, S., Malmeström, C., Wu, G., Anckarsäter, R., et al. (2009). Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Multiple Sclerosis, 15, 448–454.PubMedCrossRef

Mattsson, N., Bremell, D., Anckarsäter, R., Blennow, K., Anckarsäter, H., Zetterberg, H., et al. (2010). Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurology, 10, 51. doi:10.1186/1471-2377-10-51.PubMedCrossRef

Mattsson, N., Zetterberg, H., Bianconi, S., Yanjanin, N. M., Fu, R., Månsson, J. E., et al. (2011). Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: A cross-sectional study. Neurology, 76, 366–372.PubMedCrossRef

May, P. C., Dean, R. A., Lowe, S. L., Martenyi, F., Sheehan, S. M., Boggs, L. N., et al. (2011). Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. Journal of Neuroscience, 31, 16507–16516.PubMedCrossRef

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology, 34, 939–944.PubMed

Mungas, D. (1991). In-office mental status testing: A practical guide. Geriatrics, 46, 54–58.PubMed

Olsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., et al. (2005). Simultaneous measurement of beta-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clinical Chemistry, 51, 336–345.PubMedCrossRef

Perneczky, R., Tsolakidou, A., Arnold, A., Diehl-Schmid, J., Grimmer, T., Förstl, H., et al. (2011). CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology, 77, 35–38.PubMedCrossRef

Selnes, P., Blennow, K., Zetterberg, H., Grambaite, R., Rosengren, L., Johnsen, L., et al. (2010). Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Research, 7, 10. doi:10.1186/1743-8454-7-10.PubMedCrossRef

Shankar, G. M., & Walsh, D. M. (2009). Alzheimer’s disease: Synaptic dysfunction and Abeta. Molecular Neurodegeneration, 4, 48. doi:10.1186/1750-1326-4-48.PubMedCrossRef

Shi, X. P., Tugusheva, K., Bruce, J. E., Lucka, A., Chen-Dodson, E., Hu, B., et al. (2005). Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells. Journal of Alzheimers Disease, 7, 139–148.

Steinacker, P., Fang, L., Kuhle, J., Petzold, A., Tumani, H., Ludolph, A. C., et al. (2011). Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One, 6, e23600. doi:10.1371/journal.pone.0023600.PubMedCrossRef

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjögren, M., et al. (2000). Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters, 285, 49–52.PubMedCrossRef

Verheijen, J. H., Huisman, L. G., van Lent, N., Neumann, U., Paganetti, P., Hack, C. E., et al. (2006). Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clinical Chemistry, 52, 1168–1174.PubMedCrossRef

Yang, L. B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X. L., et al. (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nature Medicine, 9, 3–4.PubMedCrossRef

Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., et al. (2008). Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Archives of Neurology, 65, 1102–1107.PubMedCrossRef

Zhong, Z., Ewers, M., Teipel, S., Bürger, K., Wallin, A., Blennow, K., et al. (2007). Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Archives of General Psychiatry, 64, 718–726.PubMedCrossRef

Title: Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease
Authors: Christoffer Rosén
Ulf Andreasson
Niklas Mattsson
Jan Marcusson
Lennart Minthon
Niels Andreasen
Kaj Blennow
Henrik Zetterberg
Publication date: 01-03-2012
Publisher: Humana Press Inc
Published in: NeuroMolecular Medicine / Issue 1/2012
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-012-8171-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease Patients

Roles of AMP-activated Protein Kinase in Alzheimer’s Disease

Differential Expression of Genes Involved in the Degeneration and Regeneration Pathways in Mouse Models for Muscular Dystrophies

Naturally Occurring Genetic Variability in Expression of Gsta4 is Associated with Differential Survival of Axotomized Rat Motoneurons

C5a Receptor (CD88) Inhibition Improves Hypothermia-Induced Neuroprotection in an In Vitro Ischemic Model

Behavioral and Molecular Exploration of the AR-CMT2A Mouse Model Lmna R298C/R298C